Filing Flows › Acadia Pharmaceuticals (ACAD) › Q3 2026 › vs Q3 2025
Acadia Pharmaceuticals (ACAD) Q3 2026 vs Q3 2025 (year over year)
Acadia Pharmaceuticals's revenue rose $63.7M (+23%) from $279M in Q3 2025 to $342M in Q3 2026. The biggest changes: Daybue +$39.0M (+39%); Nuplazid +$24.6M (+14%). Operating margin 21.0% against 12.8% (+8.1 pts).
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 21.0% | 12.8% | +8.1 pts |
| Net margin | 15.6% | 25.8% | -10.1 pts |
| Free cash flow margin | 3.0% | 26.5% | -23.5 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Nuplazid | $202M | $178M | $24.6M | +14% |
| Daybue | $140M | $101M | $39.0M | +39% |
| Revenue | $342M | $279M | $63.7M | +23% |
| Other income, net | $8.7M | $8.8M | −$118K | -1% |
| Operating profit | $71.7M | $35.8M | $36.0M | +101% |
| Costs & expenses | $271M | $243M | $27.7M | +11% |
| Pre-tax earnings | $80.4M | $44.6M | $35.8M | +80% |
| Cost of revenue | $35.1M | $21.6M | $13.4M | +62% |
| Research & development | $76.3M | $87.8M | −$11.5M | -13% |
| SG&A | $159M | $133M | $25.8M | +19% |
| Net earnings | $53.5M | $71.8M | −$18.3M | -25% |
| Income tax | $26.9M | −$27.2M | $54.1M | — |
| Operating cash sources | $74.6M | $87.9M | −$13.3M | -15% |
| Depreciation & amortization | $3.7M | $3.0M | $703K | +24% |
| Share-based compensation | $17.5M | $13.2M | $4.3M | +32% |
| Working capital & other | $63.1M | $13.6M | $49.5M | +363% |
| Operating cash flow | $11.5M | $74.3M | −$62.8M | -85% |
| Free cash flow (OCF − capex) | $10.3M | $73.9M | −$63.6M | -86% |
| Capital expenditures | $1.2M | $388K | $852K | +220% |
Questions
How much did Acadia Pharmaceuticals's revenue grow year over year in Q3 2026?
Acadia Pharmaceuticals's revenue rose $63.7M (+23%) from $279M in Q3 2025 to $342M in Q3 2026.
What drove Acadia Pharmaceuticals's revenue change in Q3 2026?
Daybue +$39.0M (+39%); Nuplazid +$24.6M (+14%).